William D. Tap

25.2k total citations · 3 hit papers
293 papers, 8.7k citations indexed

About

William D. Tap is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology. According to data from OpenAlex, William D. Tap has authored 293 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 195 papers in Pulmonary and Respiratory Medicine, 121 papers in Oncology and 63 papers in Rheumatology. Recurrent topics in William D. Tap's work include Sarcoma Diagnosis and Treatment (165 papers), Gastrointestinal Tumor Research and Treatment (49 papers) and Vascular Tumors and Angiosarcomas (48 papers). William D. Tap is often cited by papers focused on Sarcoma Diagnosis and Treatment (165 papers), Gastrointestinal Tumor Research and Treatment (49 papers) and Vascular Tumors and Angiosarcomas (48 papers). William D. Tap collaborates with scholars based in United States, United Kingdom and Italy. William D. Tap's co-authors include Cristina R. Antonescu, Gary K. Schwartz, Sandra P. D’Angelo, Samuel Singer, Mark A. Dickson, Fritz C. Eilber, Mrinal M. Gounder, Mary Louise Keohan, Andrew Koff and Li‐Xuan Qin and has published in prestigious journals such as Nature, The Lancet and Nucleic Acids Research.

In The Last Decade

William D. Tap

275 papers receiving 8.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

2018 494 citations Sandra P. D’Angelo, Cristina R. Antonescu et al. profile →
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

2016 436 citations William D. Tap, Gary K. Schwartz et al. profile →
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

2018 274 citations William D. Tap et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William D. Tap United States	49	5.3k	3.8k	1.8k	1.2k	1.2k	293	8.7k
Sant P. Chawla United States	50	5.4k 1.0×	3.9k 1.0×	1.9k 1.1×	968 0.8×	1.2k 1.0×	300	9.7k
Suzanne George United States	55	6.8k 1.3×	3.7k 1.0×	1.8k 1.0×	1.2k 1.0×	1.3k 1.1×	257	11.7k
Jonathan C. Trent United States	48	5.1k 1.0×	2.5k 0.6×	1.3k 0.7×	778 0.7×	756 0.6×	283	8.2k
Annick D. Van den Abbeele United States	43	4.4k 0.8×	3.3k 0.9×	1.5k 0.8×	713 0.6×	674 0.6×	146	8.8k
Alberto S. Pappo United States	60	6.7k 1.3×	4.2k 1.1×	2.4k 1.3×	2.4k 2.0×	1.0k 0.9×	308	11.6k
Chandrajit P. Raut United States	52	6.0k 1.1×	4.3k 1.1×	825 0.4×	874 0.7×	1.7k 1.4×	202	9.5k
Martee L. Hensley United States	55	4.7k 0.9×	4.2k 1.1×	1.8k 1.0×	1.5k 1.2×	1.2k 1.0×	223	13.3k
C. Le Péchoux France	50	9.1k 1.7×	5.9k 1.5×	808 0.4×	975 0.8×	861 0.7×	281	11.6k
David C. Harmon United States	52	4.6k 0.9×	3.1k 0.8×	1.3k 0.7×	948 0.8×	1.3k 1.1×	128	7.1k
Sandrine Marréaud Belgium	38	4.8k 0.9×	3.8k 1.0×	1.6k 0.9×	653 0.5×	1.3k 1.1×	145	7.7k

Countries citing papers authored by William D. Tap

Since Specialization

Citations

This map shows the geographic impact of William D. Tap's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William D. Tap with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William D. Tap more than expected).

Fields of papers citing papers by William D. Tap

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William D. Tap. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William D. Tap. The network helps show where William D. Tap may publish in the future.

Co-authorship network of co-authors of William D. Tap

This figure shows the co-authorship network connecting the top 25 collaborators of William D. Tap. A scholar is included among the top collaborators of William D. Tap based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William D. Tap. William D. Tap is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chan, Jason E., William D. Tap, Cristina R. Antonescu, et al.. (2025). Deep-Learning Tool ScVital Enables Species-Agnostic Integration of Cancer Cell States. Cancer Research. 86(4). 858–872. 1 indexed citations

Yan, Fang, Douglas Barrows, Thomas S. Carroll, et al.. (2024). ATRX guards against aberrant differentiation in mesenchymal progenitor cells. Nucleic Acids Research. 52(9). 4950–4968. 3 indexed citations

Dermawan, Josephine K., David H. Abramson, Sarah Chiang, et al.. (2024). The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations. Clinical Cancer Research. 30(20). 4780–4790. 1 indexed citations

Dermawan, Josephine K., Sarah Chiang, Samuel Singer, et al.. (2024). Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma. Clinical Cancer Research. 30(10). 2260–2271. 11 indexed citations

Dermawan, Josephine K., Ciara M. Kelly, Zhidong Gao, et al.. (2023). Novel Genomic Risk Stratification Model for Primary Gastrointestinal Stromal Tumors (GIST) in the Adjuvant Therapy Era. Clinical Cancer Research. 29(19). 3974–3985. 13 indexed citations

Dermawan, Josephine K., Sarah Chiang, Martee L. Hensley, William D. Tap, & Cristina R. Antonescu. (2023). High-Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations. Modern Pathology. 36(5). 100104–100104. 5 indexed citations

Madanat‐Harjuoja, Laura, Kelly Klega, Yao Lu, et al.. (2022). Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clinical Cancer Research. 28(12). 2579–2586. 12 indexed citations

Rosenbaum, Evan, Kenneth Seier, Chaitanya Bandlamudi, et al.. (2020). HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clinical Cancer Research. 26(20). 5448–5455. 12 indexed citations

Hensley, Martee L., Shweta S. Chavan, David B. Solit, et al.. (2020). Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research. 26(14). 3881–3888. 67 indexed citations

10.

Zhu, Guo, Khédoudja Nafa, Narasimhan P. Agaram, et al.. (2019). Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical Cancer Research. 26(2). 419–427. 59 indexed citations

11.

Chiang, Sarah, Paolo Cotzia, David M. Hyman, et al.. (2018). NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. The American Journal of Surgical Pathology. 42(6). 791–798. 171 indexed citations

12.

Gialleonardo, Valentina Di, Vesselin Z. Miloushev, Kristin L. Granlund, et al.. (2017). Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. Cancer Research. 77(11). 3113–3120. 18 indexed citations

13.

D’Angelo, Sandra P., Alexander N. Shoushtari, Mary Louise Keohan, et al.. (2016). Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. Clinical Cancer Research. 23(12). 2972–2980. 98 indexed citations

14.

Ran, Leili, Inna Sirota, Zhen Cao, et al.. (2015). Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. Cancer Discovery. 5(3). 304–315. 93 indexed citations

15.

Patwardhan, Parag P., Oliver Surriga, Michael J. Beckman, et al.. (2014). Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs. Clinical Cancer Research. 20(12). 3146–3158. 94 indexed citations

16.

Slotkin, Emily K., Parag P. Patwardhan, Shyamprasad Deraje Vasudeva, et al.. (2014). MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma. Molecular Cancer Therapeutics. 14(2). 395–406. 89 indexed citations

17.

Dickson, Mark A., William D. Tap, Mary Louise Keohan, et al.. (2013). Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4 -Amplified Well-Differentiated or Dedifferentiated Liposarcoma. Journal of Clinical Oncology. 31(16). 2024–2028. 317 indexed citations

18.

George, Suzanne, Qian Wang, Michael C. Heinrich, et al.. (2012). Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial. Journal of Clinical Oncology. 30(19). 2401–2407. 200 indexed citations

19.

Braas, Daniel, Ethan Ahler, David A. Nathanson, et al.. (2012). Metabolomics Strategy Reveals Subpopulation of Liposarcomas Sensitive to Gemcitabine Treatment. Cancer Discovery. 2(12). 1109–1117. 27 indexed citations

20.

Vogelzang, Nicholas J., Sylvia Adams, Carol Aghajanian, et al.. (2011). Clinical Cancer Advances 2011: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology. 30(1). 88–109. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact